Eye Neoplasms

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Friday, November 8, 2024 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website here . About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver. Contacts Investor Relations Contact: ICR Healthcare investorrelations@delcath.com

10 scientists have been selected for OHC's first annual award to advance academic discoveries into clinical practice for rare diseases OXFORD, United Kingdom and CLEVELAND, Oct. 24, 2024 /PRNewswire/ -- The Oxford-Harrington Rare Disease Centre – a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio – today announces the first class of Oxford-Harrington Rare Disease Scholars. The scholar awards will support breakthrough treatments for rare and ultra-rare diseases across neurologic, oncologic, and metabolic disease areas, using small molecule, nucleic acid, viral, and cellular therapies. The recipients represent institutions across the UK, US, and Canada. The OHC brings together world-leading research, expertise in therapeutics development and new financial models to advance solutions to critical challenges in rare diseases. Each Scholar will receive £100,000 (UK) / $100,000 (US and Canada), personalised therapeutics development support from industry experts to help bring new therapeutics to market, and the opportunity to receive acceleration and investment funds of up to £1,000,000 based on project milestones. Matthew Wood, MD, PhD, Director and Chief Scientific Officer of the OHC, commented: "This first cohort of OHC Scholars is a testament to the outstanding quality of proposals we received from academics at institutions across the UK and North America. The breadth and standard of research into innovative approaches to treat rare diseases made our selection process very difficult, with successful proposals representing breakthrough discoveries defined by innovation, creativity and potential for clinical impact. Our congratulations go to the 2024 OHC Scholars and our sincere thanks go to all who submitted proposals – their continued efforts to make a meaningful difference for patients in need and their families are an inspiration to us all." Jonathan S. Stamler, MD, President of Harrington Discovery Institute, added: "By supporting each OHC Scholar with funding and an experienced therapeutics development team, we are maximising the potential of their discoveries to advance into the clinic. We have seen success with this approach at Harrington Discovery Institute and we are excited about replicating the model at the OHC. I look forward to seeing the progress of these innovative initiatives and sharing their advancements as the OHC continues to work towards providing scalable solutions to address the rare disease challenge globally." The 2024 OHC Rare Disease Scholar Award recipients, their organisations and fields of research are: Jacquelyn Bower, PhD – University of North Carolina at Chapel Hill, NC, USA Novel viral gene therapy to treat lethal rare eye tumours Louis Chesler, MD, PhD – Institute of Cancer Research, London, UK Regulatable cell therapies to treat brain cancers Charles Gersbach, PhD – Duke University, Durham, NC, USA Reprogramming immune cells for treatment of Hodgkin's lymphoma Xianxin Hua, MD, PhD – University of Pennsylvania, Philadelphia, PA, USA A new cellular strategy for treating acute myeloid leukaemia Michele Jacob, PhD – Tufts University School of Medicine, Medford, MA, USA A drug to treat brain abnormalities caused by CTNNB1 defects, an ultra-rare disease Bowen Li, PhD – University of Toronto, Toronto, Canada A nucleic acid therapy to treat cystic fibrosis, an inherited lung disease Michael Pacold, MD, PhD – New York University, New York City, NY, USA Drugs restoring brain function in rare metabolic diseases Carlo Rinaldi, MA, MD, PhD – University of Oxford, Oxford, UK Nucleic acid therapy for spinal and bulbar muscular atrophy (SBMA), a rare X-linked neuromuscular condition Timothy Yu, MD, PhD – Boston Children's Hospital, Boston, MA, USA Custom DNA-based therapy for a rare genetic disorder (PEX1 Zellweger Syndrome) Haiyan Zhou, MD, PhD – University College London, London, UK Nucleic acid therapy to treat loss of sensation and paralysis caused by a rare mutation For those interested in submitting a proposal for the Oxford-Harrington Rare Disease Scholar Award, the next funding call will open on the 15th of January 2025. For more information, visit: OxfordHarrington.org/funding/overview SOURCE Harrington Discovery Institute WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Plus, news about Verastem Oncology, Bright Minds Biosciences and Telix Pharmaceuticals: Aura Biosciences unveils early bladder cancer data: The Boston biotech shared that its light-activated drug led to four complete responses in five patients with low-grade non-muscle invasive bladder cancer. In high-grade NMIBC, the drug did not lead to complete responses, but two of three patients saw “visual tumor shrinkage” via a cystoscopy. Last month, Aura unveiled results in a rare eye cancer, the lead indication for its experimental drug that’s known as bel-sar for short. Aura’s shares $AURA jumped about 10% Friday morning. — Lei Lei Wu Poseida scores $15M milestone payment from Roche: Poseida received the milestone after Roche nominated a new dual CAR-T therapy per a 2022 deal. The therapy targets antigens expressed in hematologic malignancies, including multiple myeloma. The companies now have three programs in development, and their lead program is a CAR-T therapy targeting BCMA in the third-line multiple myeloma setting. — Katherine Lewin Verastem Oncology’s stock falls despite positive mid-stage data: In a Phase 2 trial, ovarian cancer patients taking avutometinib and defactinib saw median progression-free survival of 12.9 months, and those with the KRAS mutation had 22 months. The company said it plans to complete its NDA submission this month. Verastem’s stock $VSTM fell about 20% in after-hours trading on Thursday, with Mizuho analysts attributing the stock’s weakness to Verastem’s decision to first seek approval for patients with a KRAS mutation, and not those with wild-type KRAS. — Katherine Lewin Bright Minds Biosciences’ $35M private placement : The funds are set to go toward R&D expenses and general working capital. The company’s stock $DRUG soared about 70% on Friday following the announcement. Earlier this week, Bright Minds announced positive preclinical data for BMB-201, which showed that it outperformed morphine in efficacy. The company now plans to move the drug into clinical trials. — Katherine Lewin Telix Pharmaceuticals files for NASDAQ inclusion: The Australian radiopharma company said listing on the NASDAQ will increase interest from both US and global investors. Last month, Telix paid $230 million upfront to buy radioisotope manufacturer RLS Radiopharmacies. — Katherine Lewin